Bicycle Therapeutics plc (NASDAQ:BCYC) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) have been given a consensus recommendation of “Moderate Buy” by the seven ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $46.86.

A number of analysts have weighed in on the company. Needham & Company LLC reiterated a “buy” rating and issued a $43.00 target price on shares of Bicycle Therapeutics in a research note on Wednesday, April 10th. HC Wainwright reissued a “buy” rating and set a $55.00 price target on shares of Bicycle Therapeutics in a research report on Friday, May 3rd.

Insider Activity at Bicycle Therapeutics

In related news, CEO Kevin Lee sold 3,158 shares of the firm’s stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $23.81, for a total transaction of $75,191.98. Following the sale, the chief executive officer now owns 387,270 shares of the company’s stock, valued at $9,220,898.70. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold a total of 5,312 shares of company stock valued at $126,139 over the last quarter. 8.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Bicycle Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. raised its stake in Bicycle Therapeutics by 489.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,001 shares of the company’s stock valued at $72,000 after buying an additional 3,322 shares during the last quarter. Exchange Traded Concepts LLC raised its stake in Bicycle Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 6,727 shares of the company’s stock valued at $122,000 after buying an additional 1,706 shares during the last quarter. PNC Financial Services Group Inc. purchased a new position in shares of Bicycle Therapeutics in the fourth quarter worth about $137,000. PDS Planning Inc purchased a new position in shares of Bicycle Therapeutics in the first quarter worth about $210,000. Finally, Woodstock Corp raised its stake in shares of Bicycle Therapeutics by 4.5% in the fourth quarter. Woodstock Corp now owns 21,479 shares of the company’s stock worth $388,000 after purchasing an additional 926 shares during the last quarter. 86.15% of the stock is currently owned by hedge funds and other institutional investors.

Bicycle Therapeutics Stock Performance

Shares of Bicycle Therapeutics stock opened at $20.24 on Monday. The company has a current ratio of 10.42, a quick ratio of 10.42 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $865.87 million, a P/E ratio of -4.55 and a beta of 0.88. The business has a fifty day simple moving average of $22.46 and a two-hundred day simple moving average of $21.57. Bicycle Therapeutics has a 12 month low of $12.54 and a 12 month high of $27.50.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($1.25) by $0.63. Bicycle Therapeutics had a negative return on equity of 49.35% and a negative net margin of 404.14%. The company had revenue of $19.53 million for the quarter, compared to analyst estimates of $6.06 million. The business’s revenue was up 298.9% compared to the same quarter last year. On average, equities analysts forecast that Bicycle Therapeutics will post -4.44 earnings per share for the current fiscal year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.